Brought to you by 
Series B leads to €12.5mm for Curetis AG
30 Apr 2013
Executive Summary
Molecular diagnostics firm Curetis AG raised €12.5mm ($16.3mm) in its Series B financing led by first-time backer HBM Partners, which contributed €6mm and takes a board seat. Returning shareholders Aeris Capital, Life Sciences Partners, Forbion Capital, BioMedInvest, Roche Venture Fund, CD-Venture, and KfW Bankengruppe were joined by Curetis’ management, several company founders, board members, and private investors. Curetis will use the proceeds for US trials and the eventual commercialization of its Unyvero system for pneumonia and antibiotic resistance testing. (The product was launched in Europe, the Middle East, and Russia last year.) The company raised a total of $49.7mm in its three-tranche Series A financing that commenced in late 2009 and was completed in October 2011.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B leads to €12.5mm for Curetis AG
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice